Inactive Instrument

Forward Pharma A/S

Equities

FWPAY

US34986J3032

Biotechnology & Medical Research

Forward Pharma Names Rupert Sandbrink as Executive Vice President, Multiple Sclerosis/Neurology and Immunology

April 13, 2016 at 02:45 am IST

Forward Pharma also announced that Rupert Sandbrink, M.D., Ph.D. joined the Company on March 1, 2016 as Executive Vice President, Multiple Sclerosis/Neurology and Immunology. Dr. Sandbrink has more than 17 years of expertise in the pharmaceutical industry in all stages of clinical development, including product launch and medical affairs. Prior to joining the company, Dr. Sandbrink was Vice President and Therapeutic Area Head in Medical and Clinical Development and Clinical Sciences at Schering AG and later Bayer AG, with a focus on MS, other neurologic diseases and auto-immune disorders.

Latest news about Forward Pharma A/S

China Reopening Prospects Lend Some Support to European Equities But Uncertain Outlook Weighs	28/22/28	MT
European Equities Broadly Flat Amid End of Chinese COVID-19 Quarantine Restrictions	27/22/27	MT
Forward Pharma A/S(OTCPK:FWPA.Y) dropped from NASDAQ Composite Index	27/22/27	CI
European Equities Rise Modestly in Friday Trading, End Week Up 1%	23/22/23	MT
European Equities Buoyed by Financial, Pharma Stocks in Tuesday Trading	20/22/20	MT
Top Midday Decliners	20/22/20	MT
European Equities Lose Early Momentum, Remain Relatively Flat in Monday Trading	19/22/19	MT
Forward Pharma Says it Expects to Be Delisted From Nasdaq; Shares Plunge	19/22/19	MT
Biotechnology Gains Lead European Equities Higher in Wednesday Trading	14/22/14	MT
European Equities Rise Modestly Friday, But End Week Lower	09/22/09	MT
European Equities Nudge Higher on Slightly Lower Euro Area Inflation	30/22/30	MT
Rising COVID Cases in China, Plunging Oil Prices Drag European Equities Lower in Monday Trading	21/22/21	MT
European Markets Move Higher Helped by Upbeat US Inflation Data	15/22/15	MT
European ADRs Continue to Trend Higher in Monday Trading	14/22/14	MT
European ADRs Surge Higher as Global Markets React to US Inflation Data	10/22/10	MT
Forward Pharma A/S Reports Earnings Results for the Half Year Ended June 30, 2022	10/22/10	CI
European ADRs Move Higher in Tuesday Trading, Adding to Monday's Gains	08/22/08	MT
European ADRs Move Lower in Monday Trading	31/22/31	MT
European ADRs Move Higher in Thursday Trading	27/22/27	MT
European ADRs Climb Sharply Higher in Monday Trading	17/22/17	MT
European ADRs Move Higher in Thursday Trading	13/22/13	MT
European ADRs Move Higher in Friday Trading	30/22/30	MT
European ADRs Move Lower in Wednesday Trading	21/22/21	MT
European ADRs Move Lower in Tuesday Trading	20/22/20	MT
European ADRs Move Lower in Thursday Trading	15/22/15	MT

Chart Forward Pharma A/S

Duration

Period

More charts

Company Profile

Forward Pharma A/S is a Denmark-based biopharmaceutical company, that commenced development in 2005 of a formulation of DMF for the treatment of inflammatory and neurological indications. The Company granted to Biogen an irrevocable license to all of its IP through the License Agreement and received from Biogen a non-refundable cash fee of $1.25 billion in February 2017, with the return of EUR 917.7 million to shareholders through a capital reduction in September 2017. The Company has the opportunity to receive royalties from Biogen on Biogen's net sales of Tecfidera or other DMF products for multiple sclerosis outside the U.S., dependent on, among other things, a favorable outcome in Europe with respect to the 355 Patent Opposition Proceeding, including any appeal thereto.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+9.99%	115B
REGENERON PHARMACEUTICALS, INC.	+12.01%	106B
BIONTECH SE	-3.07%	24.69B
ARGENX SE	-0.67%	21.97B
GENMAB A/S	-4.64%	19.27B
BEIGENE, LTD.	-6.90%	17.56B
WUXI APPTEC CO., LTD.	-39.36%	17.32B
NEUROCRINE BIOSCIENCES, INC.	+5.82%	14.03B
SAREPTA THERAPEUTICS, INC.	+33.05%	12.13B

Bio Therapeutic Drugs